Form 4: BioXcel Therapeutics CEO Vimal Mehta Reports Routine Equity Vesting and Share Acquisition

BioXcel Therapeutics, Inc. CEO and President Vimal Mehta has reported the acquisition of common stock shares through the conversion of Restricted Stock Units (RSUs) as part of his compensation plan.

Summary

• Vimal Mehta, CEO and President of BioXcel Therapeutics, Inc. (BTAI), reported changes in his beneficial ownership of company common stock.
• On June 14, 2025, Mr. Mehta acquired 163 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• On June 15, 2025, Mr. Mehta acquired an additional 219 shares of common stock through the conversion of RSUs.
• These acquisitions resulted from the vesting of RSUs granted on March 14, 2022 (2,609 RSUs) and March 15, 2023 (3,500 RSUs), which vest over time.
• Following these transactions, Mr. Mehta directly owns 4,486 shares of common stock.
• Additionally, Mr. Mehta indirectly owns 125 shares through his spouse and 480,343 shares through BioXcel LLC, a subsidiary of BioXcel Holdings, Inc., where he holds executive and board positions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine insider transaction (RSU vesting and conversion) which is an expected part of executive compensation. It indicates the executive's continued equity stake in the company, which is generally viewed favorably as it aligns interests with shareholders. There are no negative implications from this specific filing.

Positives

• The acquisition of shares through RSU conversion indicates the vesting of executive compensation, aligning management's interests with shareholders.
• The transactions are part of a pre-scheduled equity compensation plan, reflecting a routine and expected event.

Future Outlook

This Form 4 filing primarily reports past and current insider transactions related to executive compensation and does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of insider stock transactions, specifically the vesting and conversion of Restricted Stock Units (RSUs) for a key executive. Such transactions are common across publicly traded companies as a form of executive compensation and retention, aligning management's long-term interests with shareholder value.

Related Party Transactions

• Vimal Mehta indirectly holds 480,343 shares through BioXcel LLC, which is a subsidiary of BioXcel Holdings, Inc. Mr. Mehta is an executive officer and sole board member of BioXcel Holdings, Inc., and an executive officer and manager of BioXcel LLC. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The transactions represent a routine part of executive compensation, aligning the CEO's interests with long-term shareholder value through equity ownership.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The vesting of RSUs provides a tangible benefit to the CEO, reinforcing retention and performance incentives.

Next Steps

• Continued vesting of remaining Restricted Stock Units (RSUs) for Vimal Mehta according to the established schedules of March 14, 2022, and March 15, 2023 grants, subject to continuous employment.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Vimal Mehta, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Equity Compensation, Beneficial Ownership